Cargando…
Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion
PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Ret...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701324/ https://www.ncbi.nlm.nih.gov/pubmed/31467698 http://dx.doi.org/10.1155/2019/9648614 |
_version_ | 1783445032110391296 |
---|---|
author | Abou Shousha, Mohamed Eleiwa, Taher Gibbons, Allister Smith, Christopher Edelstein, Sean Kontadakis, George Schmitz, Zachary Abernathy, Joshua Chod, Ross Bodnar, Zachary McDaniel, Kelvin Bentivegna, Rocio Akduman, Levent |
author_facet | Abou Shousha, Mohamed Eleiwa, Taher Gibbons, Allister Smith, Christopher Edelstein, Sean Kontadakis, George Schmitz, Zachary Abernathy, Joshua Chod, Ross Bodnar, Zachary McDaniel, Kelvin Bentivegna, Rocio Akduman, Levent |
author_sort | Abou Shousha, Mohamed |
collection | PubMed |
description | PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Retrospective chart review of 29 eyes of 27 patients with KPro having at least 12-month follow-up. Thirteen of these eyes had hypotony and/or retinal detachment in addition to corneal pathology and thus received KPro + PPV + SOI. Polymyxin-trimethoprim with a quinolone was used as chronic topical antibiotic prophylaxis in both groups after the first postoperative month. Outcome measures recorded at the 1-, 3-, 6-, 12-, and 24-month follow-up visits included best-corrected visual acuity (BCVA) and rates of postoperative complications. RESULTS: All the patients had completed 24-month follow-up except one case in the KPro group who lost to follow-up after 12-month visit. In the KPro + PPV + SOI group, no eyes had developed endophthalmitis by the 24-month follow-up visit versus 5 eyes of 5 patients in the uncombined KPro group (P=0.048). The 2-year cumulative endophthalmitis incidence was 31.2% in the KPro group versus zero in the KPro + PPV + SOI group (P=0.030). Four of these 5 eyes had vitreous taps with positive cultures; 2 were positive with Staphylococcus aureus, 1 with coagulase-negative staphylococci, and 1 with Streptococcus pneumoniae. Other complications included KPro extrusion (1 in each group), retinal detachment (2 in the KPro and 1 in the KPro + PPV + SOI group), newly developed glaucoma (2 in each group), and retroprosthetic membrane (9 in the KPro and 5 in the KPro + PPV + SOI group). The KPro group had better average preoperative BCVA compared to those of the KPro + PPV + SOI group (−2.29 ± 0.72 LogMAR, versus −2.95 ± 0.30 LogMAR; P=0.004). No statistically significant difference in BCVA was noted in subsequent follow-up visits. CONCLUSION: The addition of PPV and SOI to the KPro implantation in the eyes with corneal pathology, as well as hypotony and/or retinal detachment, is a safe and effective procedure for visual rehabilitation. Pars plana vitrectomy and silicone oil insertion may have a protective effect against the development of postoperative endophthalmitis in eyes receiving KPro. |
format | Online Article Text |
id | pubmed-6701324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-67013242019-08-29 Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion Abou Shousha, Mohamed Eleiwa, Taher Gibbons, Allister Smith, Christopher Edelstein, Sean Kontadakis, George Schmitz, Zachary Abernathy, Joshua Chod, Ross Bodnar, Zachary McDaniel, Kelvin Bentivegna, Rocio Akduman, Levent J Ophthalmol Clinical Study PURPOSE: To identify the incidence of endophthalmitis and visual outcomes in eyes with Boston type 1 keratoprosthesis combined with pars plana vitrectomy and silicone oil insertion (KPro + PPV + SOI) as compared to eyes receiving Boston type 1 keratoprosthesis (KPro) alone. PATIENTS AND METHODS: Retrospective chart review of 29 eyes of 27 patients with KPro having at least 12-month follow-up. Thirteen of these eyes had hypotony and/or retinal detachment in addition to corneal pathology and thus received KPro + PPV + SOI. Polymyxin-trimethoprim with a quinolone was used as chronic topical antibiotic prophylaxis in both groups after the first postoperative month. Outcome measures recorded at the 1-, 3-, 6-, 12-, and 24-month follow-up visits included best-corrected visual acuity (BCVA) and rates of postoperative complications. RESULTS: All the patients had completed 24-month follow-up except one case in the KPro group who lost to follow-up after 12-month visit. In the KPro + PPV + SOI group, no eyes had developed endophthalmitis by the 24-month follow-up visit versus 5 eyes of 5 patients in the uncombined KPro group (P=0.048). The 2-year cumulative endophthalmitis incidence was 31.2% in the KPro group versus zero in the KPro + PPV + SOI group (P=0.030). Four of these 5 eyes had vitreous taps with positive cultures; 2 were positive with Staphylococcus aureus, 1 with coagulase-negative staphylococci, and 1 with Streptococcus pneumoniae. Other complications included KPro extrusion (1 in each group), retinal detachment (2 in the KPro and 1 in the KPro + PPV + SOI group), newly developed glaucoma (2 in each group), and retroprosthetic membrane (9 in the KPro and 5 in the KPro + PPV + SOI group). The KPro group had better average preoperative BCVA compared to those of the KPro + PPV + SOI group (−2.29 ± 0.72 LogMAR, versus −2.95 ± 0.30 LogMAR; P=0.004). No statistically significant difference in BCVA was noted in subsequent follow-up visits. CONCLUSION: The addition of PPV and SOI to the KPro implantation in the eyes with corneal pathology, as well as hypotony and/or retinal detachment, is a safe and effective procedure for visual rehabilitation. Pars plana vitrectomy and silicone oil insertion may have a protective effect against the development of postoperative endophthalmitis in eyes receiving KPro. Hindawi 2019-07-25 /pmc/articles/PMC6701324/ /pubmed/31467698 http://dx.doi.org/10.1155/2019/9648614 Text en Copyright © 2019 Mohamed Abou Shousha et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Abou Shousha, Mohamed Eleiwa, Taher Gibbons, Allister Smith, Christopher Edelstein, Sean Kontadakis, George Schmitz, Zachary Abernathy, Joshua Chod, Ross Bodnar, Zachary McDaniel, Kelvin Bentivegna, Rocio Akduman, Levent Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title | Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title_full | Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title_fullStr | Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title_full_unstemmed | Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title_short | Risk of Endophthalmitis in Boston Type 1 Keratoprosthesis Combined with Vitrectomy and Silicone Oil Insertion |
title_sort | risk of endophthalmitis in boston type 1 keratoprosthesis combined with vitrectomy and silicone oil insertion |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701324/ https://www.ncbi.nlm.nih.gov/pubmed/31467698 http://dx.doi.org/10.1155/2019/9648614 |
work_keys_str_mv | AT aboushoushamohamed riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT eleiwataher riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT gibbonsallister riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT smithchristopher riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT edelsteinsean riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT kontadakisgeorge riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT schmitzzachary riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT abernathyjoshua riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT chodross riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT bodnarzachary riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT mcdanielkelvin riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT bentivegnarocio riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion AT akdumanlevent riskofendophthalmitisinbostontype1keratoprosthesiscombinedwithvitrectomyandsiliconeoilinsertion |